Check out the latest discussion with our CEO, Gerry Proehl.
关于我们
Dermata Therapeutics, Inc. (Nasdaq: DRMA) is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is currently under clinical development for the treatment of acne, psoriasis, and rosacea. Our second product candidate, DMT410, uses our Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit https://www.dermatarx.com/.
- 网站
-
https://www.dermatarx.com
Dermata Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Diego，California
- 类型
- 上市公司
- 创立
- 2014
地点
-
主要
获取路线
3525 Del Mar Heights Rd
#322
US，California，San Diego，92130
Dermata Therapeutics, Inc.员工
动态
-
Check out this great video by a Dr. Walter on DMT310 and its potential to be "game changer" in the treatment of acne.
Spongilla Lacustris: How this freshwater sponge may change how we treat ACNE! #acne #research
https://www.youtube.com/
-
Hear an update from our CEO, Gerry Proehl, on our ongoing DMT310 Phase 3 study in acne and discussions to partner our DMT410 botulinum toxin program.
Dermata Therapeutics, Inc. (NASDAQ: DRMA)
https://www.youtube.com/
-
We are excited to have been selected to present at the Global Life Science Partnering & Investor Conference this week! If you are attending and would like to meet up please reach out.
Meet the companies presenting their latest innovations at next week's Global Life Science Partnering & Investor Conference. Learn more: https://bit.ly/3uvMywg #BiocomGPIC
-
Check out the interview with Gerry Proehl, our CEO, from the Emerging Growth Conference where he provides an overview of our current programs and answers questions live.
Dermata Therapeutics, Inc. (NASDAQ: DRMA)
https://www.youtube.com/
-
Dermata is now enrolling for our Phase 3 international clinical study in acne: https://lnkd.in/gqcv6eFy and we are thrilled with the "freshwater sponge" company update provided by Dr. Harper at Maui Derm (January 2024). See you at AAD in March 2024.
Great update on DMT310 from Dr. Julie Harper at Maui Derm.
What’s on the Horizon for Acne? - Practical Dermatology
practicaldermatology.com
-
Check out the update from Gerry Proehl, our CEO, given at the Emerging Growth Conference today.
Dermata Therapeutics, Inc. (NASDAQ: DRMA)
https://www.youtube.com/
-
Dermata is now enrolling for our Phase 3 international clinical study in acne: https://lnkd.in/gqcv6eFy and we are thrilled with the "freshwater sponge" company update provided by Dr. Harper at Maui Derm (January 2024). See you at AAD in March 2024.
Great update on DMT310 from Dr. Julie Harper at Maui Derm.
What’s on the Horizon for Acne? - Practical Dermatology
practicaldermatology.com
-
Great update on DMT310 from Dr. Julie Harper at Maui Derm.
What’s on the Horizon for Acne? - Practical Dermatology
practicaldermatology.com